Literature DB >> 22824629

Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors.

Mohammad M Sajadi1, Roopa Pulijala, Robert R Redfield, Rohit Talwani.   

Abstract

We have established a cohort of natural viral suppressors (NVS) who can suppress HIV-1 replication to less than 400 copies/ml in the absence of therapy (similar to Elite Controllers/Elite Suppressors). Of the 59 patients currently in the NVS cohort, 45.8% have chronic hepatitis C virus (HCV) infection, thereby presenting a unique opportunity to study immune activation and the interaction between HCV and HIV. NVS with chronic HCV infection had elevated levels of immune activation (CD38-positive HLA-DR-positive CD8 cells) compared to NVS without chronic HCV (P = 0.004). The increased levels of immune activation were not associated with sex, HLA B57 status, or injection drug use use. NVS patients with chronic HCV had lower mean CD4 cell counts, CD4 percentage, and CD4/CD8 ratios than NVS without chronic HCV infection (P = 0.038, P = 0.008, and P = 0.048, respectively). The difference in CD4 cell count appeared to occur early in HIV infection with no difference observed in CD4 slopes between groups. Among all NVS, there was a direct correlation between mean CD4 cell count, mean CD4 percentage, and mean CD4/CD8 ratio with percentage of CD38 HLA-DR CD8 cells (P = 0.0018; P = 0.0069; and P = 0.0014, respectively). This study suggests a relationship between HCV infection, immune activation, and CD4 cell counts in the NVS, with chronic HCV infection associated with lower CD4 cell counts and higher levels of immune activation. Further studies are needed to determine if successful HCV treatment lowers immune activation levels and/or increases CD4 cell counts in these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22824629      PMCID: PMC3772623          DOI: 10.1097/QAD.0b013e328357f5d1

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

1.  Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy.

Authors:  M Andreoni; S G Parisi; L Sarmati; E Nicastri; L Ercoli; G Mancino; G Sotgiu; M Mannazzu; M Trevenzoli; G Tridente; E Concia; A Aceti
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

2.  Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children.

Authors:  Salvador Resino; Isabel Galán; Alicia Pérez; José Tomás Ramos; Jose M Bellón; Pablo Martín Fontelos; M Isabel de José; M Dolores Gurbindo Gutiérrez; Esther Cabrero; M Angeles Muñoz-Fernández
Journal:  AIDS Res Hum Retroviruses       Date:  2005-05       Impact factor: 2.205

3.  Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Authors:  Giorgio Antonucci; Enrico Girardi; Alessandro Cozzi-Lepri; Maria Rosaria Capobianchi; Andrea De Luca; Massimo Puoti; Enzo Petrelli; Giuseppe Carnevale; Giuliano Rizzardini; Paolo Antonio Grossi; Paolo Viganò; Maria Cristina Moioli; Fabrizio Carletti; Mariacarmela Solmone; Giuseppe Ippolito; Antonella D'Arminio Monforte
Journal:  Clin Infect Dis       Date:  2005-05-05       Impact factor: 9.079

4.  Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.

Authors:  Andrea De Luca; Roberto Bugarini; Alessandro Cozzi Lepri; Massimo Puoti; Enrico Girardi; Andrea Antinori; Antonio Poggio; Gabriella Pagano; Giulia Tositti; Gianpiero Cadeo; Antonio Macor; Mario Toti; Antonella D'Arminio Monforte
Journal:  Arch Intern Med       Date:  2002-10-14

5.  Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus.

Authors:  Andrea Kovacs; Roksana Karim; Wendy J Mack; Jiaao Xu; Zhi Chen; Eva Operskalski; Toni Frederick; Alan Landay; John Voris; La Shonda Spencer; Mary A Young; Phyllis C Tien; Michael Augenbraun; Howard D Strickler; Lena Al-Harthi
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

6.  Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection.

Authors:  Christoph G Lange; Michael M Lederman; Juan Sierra Madero; Kathy Medvik; Robert Asaad; Christina Pacheko; Claudia Carranza; Hernan Valdez
Journal:  J Acquir Immune Defic Syndr       Date:  2002-05-01       Impact factor: 3.731

7.  Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland.

Authors:  S A Villano; D Vlahov; K E Nelson; C M Lyles; S Cohn; D L Thomas
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

8.  Early reduction of immune activation in lymphoid tissue following highly active HIV therapy.

Authors:  J Andersson; T E Fehniger; B K Patterson; J Pottage; M Agnoli; P Jones; H Behbahani; A Landay
Journal:  AIDS       Date:  1998-07-30       Impact factor: 4.177

9.  Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus.

Authors:  J Macías; J A Pineda; F Lozano; J E Corzo; A Ramos; E León; J A García-García; J Fernández-Rivera; J A Mira; J Gómez-Mateos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-23       Impact factor: 3.267

10.  Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.

Authors:  W Phillip Law; Chris J Duncombe; Apicha Mahanontharit; Mark A Boyd; Kiat Ruxrungtham; Joep M A Lange; Praphan Phanuphak; David A Cooper; Gregory J Dore
Journal:  AIDS       Date:  2004-05-21       Impact factor: 4.177

View more
  22 in total

1.  Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation.

Authors:  Francesco Marras; Elena Nicco; Federica Bozzano; Antonio Di Biagio; Chiara Dentone; Emanuele Pontali; Silvia Boni; Maurizio Setti; Giancarlo Orofino; Eugenio Mantia; Valentina Bartolacci; Francesca Bisio; Agostino Riva; Roberto Biassoni; Lorenzo Moretta; Andrea De Maria
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

2.  Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women.

Authors:  Mark H Kuniholm; Xianhong Xie; Kathryn Anastos; Robert C Kaplan; Xiaonan Xue; Andrea Kovacs; Marion G Peters; Eric C Seaberg; Audrey L French; Mary A Young; Michael Augenbraun; Jeffrey A Martinson; Kristin A Bush; Alan L Landay; Howard D Strickler
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

3.  CD4/CD8 ratio is a promising candidate for non-invasive measurement of liver fibrosis in chronic HCV-monoinfected patients.

Authors:  Thijs Feuth; Debbie van Baarle; Karel J van Erpecum; Peter D Siersema; Andy I M Hoepelman; Joop E Arends
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-22       Impact factor: 3.267

4.  Influence of Injection Drug Use-Related HIV Acquisition on CD4 Response to First Antiretroviral Therapy Regimen Among Virally Suppressed Individuals.

Authors:  Keri L Calkins; Catherine R Lesko; Geetanjali Chander; Richard D Moore; Bryan Lau
Journal:  J Acquir Immune Defic Syndr       Date:  2018-03-01       Impact factor: 3.731

Review 5.  Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.

Authors:  Babafemi Taiwo; Luis Barcena; Randall Tressler
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

Review 6.  Future directions: lung aging, inflammation, and human immunodeficiency virus.

Authors:  Meghan Fitzpatrick; Kristina Crothers; Alison Morris
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

7.  Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals.

Authors:  Rui André Saraiva Raposo; Mohamed Abdel-Mohsen; Sara J Holditch; Peter J Kuebler; Rex G Cheng; Emily M Eriksson; Wilson Liao; Satish K Pillai; Douglas F Nixon
Journal:  J Leukoc Biol       Date:  2013-08-08       Impact factor: 4.962

Review 8.  Virologic and immunologic aspects of HIV-hepatitis C virus coinfection.

Authors:  Kara W Chew; Debika Bhattacharya
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

9.  Altered T-cell subsets in HIV-1 natural viral suppressors (elite controllers) with hepatitis C infection.

Authors:  Mohammad M Sajadi; Robert R Redfield; Rohit Talwani
Journal:  AIDS       Date:  2013-07-31       Impact factor: 4.177

Review 10.  Pulmonary disease in HIV-infected adults in the era of antiretroviral therapy.

Authors:  Meghan E Fitzpatrick; Ken M Kunisaki; Alison Morris
Journal:  AIDS       Date:  2018-01-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.